Skip Navigation LinksHome > Professional Development > AABB Symposium on Implementation of Pathogen‐Reduced Blood Components Agenda

AABB Symposium on Implementation of Pathogen‐Reduced Blood Components Agenda

Marriott North Bethesda Conference Center
Bethesda, Maryland
April 27 – 28, 2015


April 27, 2015

11:00am Registration Opens
12:30pm Panel #1
Moderator: Richard Kaufman, MD
Welcome and Opening Remarks
Lynne Uhl, MD
Pathogen Inactivation: Rationale and Some History
Harvey G. Klein, MD
Pathogen Inactivation Technologies: What are We Going to Get Out of Them?
Jim AuBuchon, MD, FCAP, FRCP(Edin)
Pathogen-Reduced Platelet Phase I / Phase II Study Results
Ed Snyder, MD, FACP
Clinical Effects of Transfusion of Pathogen-Reduced Platelets and Impact on Platelet Utilization
Jeffrey McCullough, MD
Panel #1 Questions and Answers 
3:30pm Break
3:50pm Panel #2
Moderator: Roger Dodd, PhD
Current US Licensure Status
Salim Haddad, MD
Projections of Future Submissions/Approvals: Cerus
Carol Moore
Projections of Future Submissions/Approvals: TerumoBCT
Ray Goodrich, PhD
Projections of Future Submissions/Approvals: Macopharma
Frank Tolksdorf, PhD
Safer Platelets: The Alternative Approaches
Zbigniew Szczepiorkowski, MD, PhD, FCAP
Update on the Cost Effectiveness of Pathogen Inactivation Technologies
Brian Custer, PhD, MPH
Pathogen Reduction: Are We Reducing Legal Risk?
James Barbeau, MD, JD
Panel #2 Questions and Answers 
6:30pm Close of Day 1

April 28, 2015

7:30am Continental Breakfast
8:30am Panel #3
Moderator: Michael Murphy, MD, FRCP, FRCPath, FFPath
Nationwide Implementation of Pathogen-Inactivated Platelet Concentrates in Switzerland
Markus Jutzi, MD
Pathogen-Reduced Platelets: Experience and Perspectives from France
Pierre Tiberghien, MD, PhD
PRT for Platelets in Ireland: The Decision-making and Implementation Processes
Willy Murphy, MD, FRCPEdin, FRCPath
Pathogen Inactivation of Platelets: Recommendations for the UK Blood Services from SaBTO, 2014
Michael Murphy, MD, FRCP, FRCPath, FFPath
Pathogen Reduction: The Thinking at Canadian Blood Services
Dana Devine, PhD
Pathogen Reduction Technologies: The Héma-Québec Perspective
Marc Germain, MD, FRCP(C), PhD
Panel #3 Questions and Answers
10:40am Break
11:00am Panel #4
Moderator: Mary Beth Bassett, BS, MT(ASCP)
Safety and Availability
Jay E. Menitove, MD
Implementation: A View from the Hospital
Richard Kaufman, MD
Implementation of Pathogen Reduced Blood Components: The Yale Approach
Ed Snyder, MD, FACP
Financial Implications of a PRT Conversion
Jeffrey McCullough, MD
12:05pm Lunch on your own
1:15pm Panel #5
Moderator: Jim AuBuchon, MD, FCAP, FRCP(Edin)
Blood Bank of Delaware’s Implementation Plans for Pathogen Reduction
Christopher Nare, MT (AMT), MS
The Path to Pathogen Reduction Payment: Thinking Outside the Box
Christine Zambricki, DNAP, CRNA, FAAN
Pathogen Reduction: The Red Cross Perspective
Susan L. Stramer, PhD
Panel #5 Open Forum, Discussion and Questions and Answers
Symposium Summary
Lynne Uhl, MD
2:00pm End of Symposium